Cromsource ‘evolves’ hybrid services model with changing customer needs

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Radachysnkyi)
(Image: Getty/Radachysnkyi)

Related tags: Cromsource, FSP, CRO

In response to demand for flexibility, Cromsource has consolidated its hybrid services model to provide customers with an alternative to fully outsourced or functional service provider (FSP) models.

Citing constant change in the industry, Debbie Kent, global head of the TalentSource Life Sciences Department at Cromsource, said the company’s clients are demanding “innovation and flexibility in the way they are outsourcing their work.” 

“Being agile is critical and this model, although within our service offering for many years, now evolves to provide clients with an alternative to full-service outsourcing if they do not have a structure in place or they want to supplement their existing structure with a full-team approach,”​ Kent told us.

Speaking to the benefits of this approach, Kent said it enables customers to rely on a single provider that can provide scalability for short- or long-term commitments. Services can be ‘bundled’ together for flexibility in the allocation of internal oversight and external resources to either ramp-up or down, she added.

“Cromsource can provide full support in the design on the hybrid service model, with a solid CRO infrastructure and long experience in flexible model delivery,” ​Kent said. “Critical to success is in the design and support of the hybrid solution and our model combines the seamless cooperation between Cromsource Clinical Operations and our in-house flexible resourcing department – TalentSource Life Sciences.” 

With headquarters in Waltham, MA and Verona, Italy, Cromsource this month also opened a newly expanded office​ in Cary, NC. The office location complements its two existing US offices, according to the company, which has grown its US business by more than 150% in the past two years.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars